Adaptive Biotechnologies Corp
NASDAQ:ADPT
EV/S
Enterprise Value to Sales
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
Market Cap | EV/S | ||||
---|---|---|---|---|---|
US |
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
391.7m USD | 0.3 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.6B USD | 5.7 | ||
US |
Danaher Corp
NYSE:DHR
|
181.8B USD | 8.1 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.6B USD | 3.6 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.9B CHF | 5.8 | ||
US |
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 6.1 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
54.8T KRW | 14.6 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
26.8B USD | 7.6 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.8B USD | 8.8 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.4B USD | 3.5 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
18.9B EUR | 7.8 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.